BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Josep Tabernero, Jason J. Luke, Anthony M. Joshua, Andrea I. Varga, Victor Moreno, Jayesh Desai, Ben Markman, Carlos Alberto Gomez-Roca, Filippo G. De Braud, Sandip Pravin Patel, Matteo S. Carlino, Lillian L. Siu, Giuseppe Curigliano, Zhaohui Liu, Yuko Ishii, Penny Phillips, Megan Wind-Rotolo, Paul Andrew Basciano, Alex Azrilevich, Karen A. Gelmon
Institutions: Vall d'Hebron Hospital Universitari, University of Chicago Medical Center, St Vincent's Hospital Sydney, Institut Gustave Roussy, Hospital Universitario Fundación Jiménez Díaz, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Monash Health, Monash University, Institut universitaire du cancer de Toulouse Oncopole, Fondazione IRCCS Istituto Nazionale dei Tumori, Moores Cancer Center, The University of Sydney, Melanoma Institute Australia, Princess Margaret Cancer Centre, University of Milan, European Institute of Oncology, Bristol-Myers Squibb (United States), BC Cancer Agency, University of British Columbia
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891880652